DDInter6 DDInter1397
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham.[L7712,L7715] A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.[L7700,L7742]
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Epoprostenol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Paroxetine
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolmetin
Tolmetin {u} (Compound) downregulates {v} (Gene) IARS2
IARS2 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Epoprostenol {u} (Compound) causes {v} (Side Effect) Epistaxis
Epistaxis {u} (Side Effect) is caused by {v} (Compound) Paroxetine
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acetylsalicylic acid
Acetylsalicylic acid {u} (Compound) binds {v} (Gene) NFKBIA
NFKBIA {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) upregulates {v} (Gene) CSTA
CSTA {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) palliates {v} (Disease) endogenous depression
endogenous depression {u} (Disease) is palliated by {v} (Compound) Paroxetine
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) downregulates {v} (Gene) HERPUD1
HERPUD1 {u} (Gene) is upregulated by {v} (Compound) Paroxetine
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Abciximab {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Clopidogrel {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Paroxetine
Abciximab {u} may lead to a major life threatening interaction when taken with {v} Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} (Compound) upregulates {v} (Gene) DNTTIP2
DNTTIP2 {u} (Gene) is downregulated by {v} (Compound) Paroxetine
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Paroxetine (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) downregulates IARS2 (Gene) and IARS2 (Gene) is downregulated by Paroxetine (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) causes Epistaxis (Side Effect) and Epistaxis (Side Effect) is caused by Paroxetine (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) binds NFKBIA (Gene) and NFKBIA (Gene) is upregulated by Paroxetine (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) upregulates CSTA (Gene) and CSTA (Gene) is upregulated by Paroxetine (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) palliates endogenous depression (Disease) and endogenous depression (Disease) is palliated by Paroxetine (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) downregulates HERPUD1 (Gene) and HERPUD1 (Gene) is upregulated by Paroxetine (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Paroxetine (Compound)
Abciximab may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Paroxetine (Compound)
Abciximab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate (Compound) upregulates DNTTIP2 (Gene) and DNTTIP2 (Gene) is downregulated by Paroxetine (Compound)